---
figid: PMC4447524__nihms666383f1
figtitle: Resistance to BCR-ABL1 tyrosine kinase inhibitors may take the form of (left)
  point or compound mutation-based, BCR-ABL1-dependent resistance or (middle) recruitment
  of alternative pathway signaling upon effective inhibition of BCR-ABL1
organisms:
- Homo sapiens
- Mus musculus
- Bellapiscis medius
- NA
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC4447524
filename: nihms666383f1.jpg
figlink: /pmc/articles/PMC4447524/figure/F1/
number: F1
caption: Resistance to BCR-ABL1 tyrosine kinase inhibitors may take the form of (left)
  point or compound mutation-based, BCR-ABL1-dependent resistance or (middle) recruitment
  of alternative pathway signaling upon effective inhibition of BCR-ABL1. (right)
  A subset of patients achieving deep remissions on TKI therapy who elect to stop
  therapy subsequently demonstrate apparently durable treatment-free remission (TFR).
papertitle: 'Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and
  Mechanisms of Resistance to Tyrosine Kinase Inhibitors.'
reftext: Christopher A. Eide, et al. Curr Hematol Malig Rep. ;10(2):158-166.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9276825
figid_alias: PMC4447524__F1
figtype: Figure
redirect_from: /figures/PMC4447524__F1
ndex: 6fd0763d-df03-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4447524__nihms666383f1.html
  '@type': Dataset
  description: Resistance to BCR-ABL1 tyrosine kinase inhibitors may take the form
    of (left) point or compound mutation-based, BCR-ABL1-dependent resistance or (middle)
    recruitment of alternative pathway signaling upon effective inhibition of BCR-ABL1.
    (right) A subset of patients achieving deep remissions on TKI therapy who elect
    to stop therapy subsequently demonstrate apparently durable treatment-free remission
    (TFR).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CP
  - BCR
  - SNHG33
  - ABL1
  - TRI-AAT9-1
  - FGF2
  - FGF13
  - SRC
  - FGR
  - FYN
  - YES1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - JAK2
  - STAT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - TFRC
  - AGRP
  - ARTN
  - MRC1
  - POR
  - VDAC2
  - ARHGEF1
  - MAP6
  - Cp
  - Fgf2
  - Src
  - Mdk
  - Jak2
  - Stat3
  - Pik3r1
  - Tfrc
  - Agrp
  - Art2b
  - Dclre1c
  - Atp9b
  - Por
  - Arfip2
  - Arhgef1
  - Map6
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - cp
  - cml
  - tri
  - bnl
  - Src42A
  - Csk
  - Src64B
  - Dsor1
  - Mtk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - as
  - art
  - Dll
  - por
  - rt
  - l(1)sc
  - Start1
  - stop
  - H bosutinib
  - nilotinib
  - H ponatinib
  - ponatinib
---
